Plaintiff Grant & Eisenhofer PA, headquartered in Wilmington, Delaware, filed its lawsuit in the U.S. District Court for the Central District of California August 10. The law firm represents a California whistleblower in a False Claims Act lawsuit over the off-label promotion of cancer drugs. It is seeking more than $7 million in fees and costs. The defendants include California resident Beverly Brown and law firms Richard Harpootlian PA and Bienert Miller & Katzman PLC.
Ms Brown, who worked as a Celgene Corp. sales representative, filed her whistleblower complaint in 2010 over the off-label use of drugs Thalomid and Revlimid. According to Celgene, the litigation related primarily to allegations that it promoted Thalomid for off-label uses before its 2006 U.S. Food and Drug Administration approval for newly-diagnosed multiple myeloma, a form of blood cancer that develops in the bone marrow. Celgene reported last month that the pharmaceutical company would pay a total of $280 million to the U.S. federal government, 28 states, the District of Columbia and the City of Chicago.
Read full article at LegalNewsLine.com
Summarized by Natalia Tsar.